NYSE · CDREHealthcareOrthopedic & Surgical Supplies

Cadre Holdings financials

$25.53−2.03%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$610.3M$567.6M$482.5M$457.8M$427.3M
Gross profit$259.6M$233.5M$200.7M$175.7M$170.7M
Gross margin42.5%41.1%41.6%38.4%39.9%
Operating income$67.4M$66.8M$56.5M$16.7M$51.7M
Net income$44.1M$36.1M$38.6M$5.8M$12.7M
Net margin7.2%6.4%8.0%1.3%3.0%
Diluted EPS$1.02$0.90$1.02$0.16$0.44
EBITDA$95.0M$93.0M$74.4M$41.0M$68.9M
Operating cash flow$63.7M$31.8M$73.2M$46.4M$40.1M
Free cash flow$56.8M$26.1M$66.5M$41.9M$37.3M
Diluted shares43.4M40.3M37.9M36.1M28.6M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$122.9M$124.9M$87.7M$45.3M$33.9M
Short-term investments$0.00$0.00$0.00$0.00—
Total debt$307.3M$223.2M$140.1M$149.7M$159.7M
Total assets$770.0M$652.7M$431.2M$392.0M$311.8M
Total liabilities$452.2M$341.2M$234.0M$226.1M$223.2M
Shareholders' equity$317.8M$311.5M$197.2M$165.9M$88.6M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology